10c- Intro to Hemostasis- Clotting Disorders Flashcards

1
Q

What are 2 factors that promote thrombosis and what are some examples of each?

A
  • Endothelial Injury
    • trauma, surgery, fracture, burn, ulcerated atherosclerotic plaques, vasculites, smoking, sepsis
  • Abnormal blood flow
    • atherosclerosis, prolonged bed rest, atrial fibrilation, myocardial infarct, prosthetis heart valves, aneurysms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are 6 inherited hypercoagulability states?

A

Factor 5 Leiden

Prothrombin 20210A mutation

Hyperhomocysteinemia

dysfibrinogenemia

Protein C deficiency (also acquired)

Prtein S deficiency (also acquired)

at3 deficiency (also acquired)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are some acquired hypercoagulability factors?

A

malignancy,

estrogens,

antiphospholipid antibody syndrome,

heparin-induces thrombocytopenia,

disseminated intravascular coagulation (DIC),

thrombotic thrombocytopenic purpura,

paroxysmal nocturnal hemoglobinuria,

myeloproliferative neoplasms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Which 3 thrombophilia risk factors can be both acquired or inherited? Are they more commonly acquired or inherited?

A

protein C, S, at3 deficiencies

hyperhomocysteinemia

dysfibrinogenemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what are 3 sources of thrombi?

A
  • Venous
    • sites of stasis, travel in direction of blood flow , DVT in leg veins, may travel through heart to pulmonary veins (PE)
  • Heart: atrial or ventricular walls or valve leaflets
    • right heart: embolus may detach and travel into lung
    • left heart: embolus may detach and travel into systemis arterial circulation
  • Arterial
    • develop at sites of endothelial injury, turbulence,
    • travel retrograde, atherosclerotic plaque (abdominal aorta, carotid artery)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Which thrombi diseases usually occur in veins and which in arteries?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is Factor 5 Leiden? What causes it?

A
  • most common inherited predisposition to thrombosis (venous)
  • single point mutation in F5 gene which is the cleavage site for protein C
  • heterozygous: 2-15% of caucasians are hetero, 5-7X risk
  • homozygous: 50X risk for thrombosis
  • most pts won’t have thrombosis unless coupled with other risk factors
  • Activated protein C resisitance= mutated F5 is resistant to protein C inactivation so protein F5 is active longer and promotes clotting
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How do we test for Factor V Leiden? Who should we not test?

A

Molecular analysis (PCR, microarray) for mutation (cheap automated)

Don’t test for thrombophilia in adult patients with venous thromboembolism (VTE) occuring in the setting of major transient risk factors (surgery, trauma, or prolonged immobility)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the significance of the Prothrombin 20210A mutation

A
  • it is the 2nd most common inherited predisposition for thrombosis (venous)
  • single base pair mutation in prothrombin (F2) gene
  • heterozygous vs homozygotes
    • heterozygotes have 2-3X risk for thrombosis and 2-4% of caucasians are heteros
    • homoszygote state is rare
  • unclear mechanism of hypercoagulability, but may be related to elevated prothrombin levels
  • diagnosis: molecular analysis for gene mutation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What does it mean to say someone is a double heterozyote?

A

Heterozygote for factor V leiden and prothrombin gene mutation

they are at a greater risk of thrombosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How does someone get an ATIII, Protein C and Protein S deficiency? What is it associated with?

A
  • inherited forms
    • 5-15% of family thrombosis, risk increases after puberty and present in adolescence/young adulthood
  • acquired forms
    • consumptive (recent clot, DIC), decreased synthesis (liver failure, vitamin K deficiency)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How do we assess for protein C and protein S deficiencies in lab? WHen should we not assess?

A

ATIII, Protein C and S activities, Protein S free antigen

Do not test levels during active clotting bc the tests are not analytically accurate during an active clot

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What happes with antiphospholpid antibody syndrome? What is ti assocaited with? What are the 2 kinds? What does it cause in vitro and how is that different in vivo?

A

acquire antibodies against various phospholipid complexes

associated with arterial, venous thrombosis with high recurrence rates and repeat miscarriages (DVTs, chronic PES, stroke, renal failure, interference with placenta growth/devo)

Primary ( no known association) secondary (associated with lupus)

in vitro: inhibit clotting, in vivio promote clotting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the 2 criteria for diagnsing antiphospholipid antibody syndrome?

A

Positive laboratory test (only need 1)

  • lupus anticoagulant test
  • antiphospholipid antibody ELISA

Positive clinical finding

  • thrombosis
  • recurrent miscarriage
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the 2 laboratory evaluations for antiphospholipid anitbody syndrome?

A

Lupus anticoagulant

  • functional assessment
  • prolongation of clotting based tests

Anti-cardiolipin, anti- B2 glycoprotein

  • ELISA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are antiphospholipid antibodies used to diagnose (LA)? what 4 things lead to the diagnosis? What would tests results would you expect?

A

antiphospholipid antibody syndrome!

  1. Prolongation of 1 clotting assay, sensitive to lupus anticoagulants (dRVVT, aPTT; NOT PT)
  2. Failure to correct on mixing study
  3. correction of a clotting time with addition of excess phospholipid
  4. presistently present> 12 wks

**aPTT prolonged, 1:1 mix aPTT prolnged, aPTT with excess PLs normal**

17
Q

What are the 3 thrombotic states associated with thrombocytopenia?

A

Heparin-induced thrombocytopenia (HIT)

Thrombotic microangiopathies

Disseminated intravascular coagulation (DIC)

18
Q

What are the 3 thrombotic microangiopathies?

A

thrombotic thrombocytopenia purpura (TTP)

Hemolytic uremic syndomre (HUS)

DIsseminated intravascular coagulation (DIC)

19
Q

What is Heparin-induced thrombocytopenia? (HIT) What ais the major clinical manifestation? In what type of heparin is it mainly observed?

A

thrombocytopenia (<150,000/uL) or >50% drop in platelet count during heparin therapy

Major manifestation is thrombosis! venous and arterial

Most commonly observed in unfractionated heparin, rarely in LMWH

cardiac>surgical>medical pts.

20
Q

How long after heparin initiation do ppl develop HIT?

A

5-10 days after initiation of heparin; uncommonly seen within 14 hours if previously exposed

21
Q

What is the pathophysiology of HIT?

A

Drug induced antibody production

antibodies made against heparin-PF4 complex (IgGs)

immune complexes bind to platelets through Fc receptor

platelets activate and initiate clot formation

22
Q

What is the 4Ts system for measuring risk of HIT? Is a high or low score equivalent to high risk? What criteria need to be met to be considered high risk?

A

high score=high risk! scale of 0-2

To score a 2:

Thrombocytopenia-extent of fall in platelet count: >50% fall or nadir> 20*10^9

Timing-onset of fall in platelet count or thrombosis in relation to inititaion of heparin: after 5-10 days or <1 day within recent heparin exposure

Thrombosus or other sequelae- proven new thrombosis; skin necrosis; acute systemic reaction after intravenous unfractionated heparin bolus

Other causes of thrombocytopenia- none evident

23
Q

When shoul dyou not test or treat for suspected heparin-induced thrombocytopenia?

A

in pts with low pre-test probabiblity of HIT (low 4T’s score)

24
Q

What is the screening test for HIT? What is the confirmatory test?

A

Screen

  • ELISA for PF4- heparin IgG
  • 95% sensitivity, 80% specificity

Confirmatory

  • serotonin- release
  • 88% sensitivity, 100% specificity
25
Q

What is the treatment for HIT?

A

Stop heparin!

Non-heparinoid anticoagulants, direct thrombin inhibitors, warfarin

26
Q

What are thrombotic microangiopathies? What are 3 symptoms?

A

disease characterized by widespread thrombi deposition in the microvasculature

  • Hemolytic anemia (MAHA)
  • Organ dysfunction
  • Thrombocytopenia due to consumptiion
27
Q

What is Thrombotic Thrombocytopenic Purpura? (TTP) What symptoms are associated? Who gets it?

A

Deficiency of metalloproteinase, ADMTS

  • usually autoimmune= ADAMTS13 antibodies
  • leads to too large vWF multimers

Classic pentad: fever, renal and neurologic impairment, thrombocytopenia, MAHA

acquired MUCH more than congenital, 30-50 y/o, female>male

28
Q

What does TTP lead to?

A

Platelet activation and thrombi formation

The big vWF factor multimers are BIG and STICKY so they form clots and stick to things that they shouldn’t!

29
Q

What would laboratory evaluation of TTP show?

A

Red cell fragments (schistocytes; circled)

decreased platelets

decreased ADAMTS13 levels (initiate treatment before this lab is back!)

30
Q

How do we treat TTP?

A

must be inititated rapidly!

plasma exchange (remove antibodies, resupply ADAMTS-13)

31
Q

What s “typical” hemolytic uremic syndrome associated with? WHat are the consequences?

A

Shiga toxin producing E. coli (O157: H7)

consequences:

  • local effects of colonic cells lead to pain and bloody diarrhea
  • systemic toxin effects (endothelial cells) lead to systemic disease.
    • renal endothelial cell are particularly sensitive to toxin which leads to thrombosis.
    • younger children are more susceptible
  • CNS dysfunction may occur
32
Q

What is the median time for HUS? What is the epidemiology consistent with? what tests are helpful?

A
  • Median time to HUS is 1 week
  • Spidemiology is consistent with infectious agent
  • stool studies often informative, especially if obtained early , EIA test often positive for shiga toxin
  • ADAMTS13 activity is not decreased, no coagulation evidence for DIC
33
Q

What is atypical HUS associated with? What makes it atypical?

A

associated with complement defects

atypical because no bloody diarrhea, may be episodic w recurrent flairs of activity

familial cases usually do not precent concurrently,

progression to renal failure is more common

***don’t need to know details but they are pictured

34
Q

What is DIsseminated intravascular coagulation (DIC) characterized by? What is it?

A
  • characterized initially by clotting in the microvasculature (microangiopathy), resulting in organ ischemia, followed by bleeding tendencies
  • consumptive coagulopathy
    • widespread, excessive clotting leading to comsumption of facotrs and platelets
    • once the factors are consumed bleeding occurs
    • activation of fibrinolysis (hyperfibrinolysis) = bleeding
35
Q

What is DIC associated with?

A

It is not a primary disease

it is associated with severe illnesses (sepsis, trauma, obstetric complications, fat emoblus, cancer (acute promyelocytic leukemia), burns, ischemia)

due to relase of tissue factor and endothelial injury

36
Q

What is the pathology of DIC? What can it result in?

A
  • acute= bleeding tendency
  • chronic= thrombotic tendency (metastatic carcinoma)
  • End organ ischemic damage
    • kidney disease (glomerular thrombi)
    • brain microinfarcts
    • hyaline membranes? ARDS (alveolar thrombi)
    • adrenal necrosis and hemorrhage
    • myocardial damage
  • Microangiopathic hemolytic anemia: red cells lyse as they transit through occlusions in small vessels
37
Q

What are the laboratory results of DIC?

A
  • Prolonged
    • PT
    • aPTT
  • Elevated D-Dimers
  • decreased fibrinogen
  • decreased platelets
38
Q

What is the treatment of DIC?

A

treat the inciting cause

supportive care: restore tissue perfusion, blood products

39
Q

Summary! Fill in the chart :)

A